alzheimer’s disease

Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia.

Authors: Ames D, Bourgeat P, Fowler C, Laws SM, Lim YY, Martins RN, Maruff P, Masters CL, Pietrzak RH, Rainey-Smith S, Rowe CC, Salvado O, Snyder PJ, Villemagne VL

Journal: Journal of Molecular Neuroscience

In a group of older adults with very mild dementia, we aimed to characterize the nature and magnitude of cognitive decline as measured by the Cogstate Brief Battery, in relation to Aβ levels and hippocampal volume. […]

Methodological Aspects of the Phase II Study AFF006 Evaluating Amyloid-beta -Targeting Vaccine AFFITOPE® AD02 in Early Alzheimer’s Disease – Prospective Use of Novel Composite Scales.

Authors: Dubois B, Ellison N, Hendrix S, Mattner F, Schmidt W, Schneeberger A, Stanworth S, Tierney L

Journal: The Journal of Prevention of Alzheimer's Disease

BACKGROUND: Optimized scales and composite outcomes have been proposed as a way to more accurately measure Alzheimer’s disease related decline. AFFITOPE® AD02, is an amyloid-beta (Aβ)-targeting vaccine to elicit anti-Aβ antibodies. IMM-AD04, commonly known as Alum, […]

Detection of MCI in the clinic: Evaluation of the sensitivity and specificity of a computerised test battery, the Hopkins Verbal Learning Test and the MMSE.

Authors: Budge MM, de Jager CA, Honey TE, Schrijnemaekers AC

Journal: Age Ageing

INTRODUCTION: The sensitive detection of mild cognitive impairment (MCI) in older adults is an important problem that requires objective assessment. We evaluated whether the computerised cognitive test battery, CogState, was as sensitive to MCI as two […]

Back to Publications